JP2024521767A5 - - Google Patents

Info

Publication number
JP2024521767A5
JP2024521767A5 JP2023572717A JP2023572717A JP2024521767A5 JP 2024521767 A5 JP2024521767 A5 JP 2024521767A5 JP 2023572717 A JP2023572717 A JP 2023572717A JP 2023572717 A JP2023572717 A JP 2023572717A JP 2024521767 A5 JP2024521767 A5 JP 2024521767A5
Authority
JP
Japan
Prior art keywords
nucleic acid
composition according
disease
complement
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521767A (ja
Filing date
Publication date
Priority claimed from GBGB2107586.6A external-priority patent/GB202107586D0/en
Application filed filed Critical
Publication of JP2024521767A publication Critical patent/JP2024521767A/ja
Publication of JP2024521767A5 publication Critical patent/JP2024521767A5/ja
Pending legal-status Critical Current

Links

JP2023572717A 2021-05-27 2022-05-26 Ｈ因子ファミリータンパク質のための阻害性核酸 Pending JP2024521767A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2107586.6 2021-05-27
GBGB2107586.6A GB202107586D0 (en) 2021-05-27 2021-05-27 Inhibitory nucleic acids for Factor H family proteins
PCT/EP2022/064376 WO2022248651A2 (en) 2021-05-27 2022-05-26 Inhibitory nucleic acids for factor h family proteins

Publications (2)

Publication Number Publication Date
JP2024521767A JP2024521767A (ja) 2024-06-04
JP2024521767A5 true JP2024521767A5 (enExample) 2025-06-03

Family

ID=76741290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572717A Pending JP2024521767A (ja) 2021-05-27 2022-05-26 Ｈ因子ファミリータンパク質のための阻害性核酸

Country Status (8)

Country Link
US (1) US20240209367A1 (enExample)
EP (1) EP4347030A2 (enExample)
JP (1) JP2024521767A (enExample)
CN (1) CN118632711A (enExample)
AU (1) AU2022279580A1 (enExample)
CA (1) CA3219247A1 (enExample)
GB (1) GB202107586D0 (enExample)
WO (1) WO2022248651A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165568A2 (en) * 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
GB0611606D0 (en) 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration
WO2009059321A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
US9598733B2 (en) 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
US20150157675A1 (en) 2012-04-02 2015-06-11 Sung Kyun Biotech Co., Ltd. Composition comprising eupatorium spp. extract as active ingredient for preventing and treating obesity and metabolic bone disease
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
GB201709222D0 (en) 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
WO2019051443A1 (en) 2017-09-11 2019-03-14 Insideoutbio, Inc. METHODS AND COMPOSITIONS FOR IMPROVING IMMUNOGENICITY OF TUMORS
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2019215330A1 (en) 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration
EP4214515A1 (en) 2020-09-16 2023-07-26 Complement Therapeutics Limited Complementome assay

Similar Documents

Publication Publication Date Title
JP7687685B2 (ja) 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド
JP7661228B2 (ja) オリゴヌクレオチド組成物及びその方法
JP7406793B2 (ja) ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
JP7564125B2 (ja) スプライシング及び翻訳を調節するための方法及び組成物
AU2017210042B2 (en) Compositions and methods for inhibiting Factor D
JP2010500025A5 (enExample)
US20190167811A1 (en) Lipid compositions and their uses for intratumoral polynucleotide delivery
JP2020105205A (ja) トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療方法
US11814622B2 (en) OPA1 antisense oligomers for treatment of conditions and diseases
US20250354148A1 (en) DUAL-ACTING siRNA BASED MODULATION OF C9orf72
WO2008021136B1 (en) Methods and sequences to suppress primate huntington gene expression in vivo
CN108291225A (zh) 单链反义寡核苷酸在预防或治疗涉及三核苷酸重复扩增的遗传疾病中的用途
US20150141320A1 (en) Compositions and methods for modulating gene expression
JP2022544702A (ja) スプライシングおよびタンパク質発現を調節するための組成物および方法
EP3708184A1 (en) Methods and agents for treating alzheimer s disease
JP2014518612A5 (enExample)
JP7660515B2 (ja) 病態及び疾患の治療用アンチセンスオリゴマー
US20250059535A1 (en) Opa1 antisense oligomers for treatment of conditions and diseases
EP3122365B1 (en) Transthyretin allele selective una oligomers for gene silencing
JP2023524130A5 (enExample)
JP2024521767A5 (enExample)
CN119403926A (zh) 用于减少富亮氨酸重复激酶2（lrrk2）的表达的寡核苷酸及其用于预防和/或治疗人类疾病的用途
Ayala et al. RNA-based therapies for neurodegenerative diseases
US20230304012A1 (en) Muscle regeneration and growth
JP2024524974A (ja) ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー